

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Ophthalmic disease				
Corneal wound	Tumor necrosis factor- α -induced protein 6 (TNFAIP6; TSG-6)	A study in mice suggests recombinant TSG-6 could help treat corneal damage. In mice, injection of Tsg-6 within eight hours of cornea injury decreased corneal inflammation, neovascularization and opacity compared with injection of control buffer. Next steps include testing TSG-6 in rabbit models of cornea injury. SciBX 3(37); doi:10.1038/scibx.2010.1127 Published online Sept. 23, 2010	Patent application filed; licensing status undisclosed	Oh, J.Y. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Sept. 13, 2010; doi:10.1073/pnas.1012451107 Contact: Darwin J. Prockop, Texas A&M Health Science Center College of Medicine at Scott and White, Temple, Texas e-mail: prockop@medicine.tamhsc.edu